Emerging epidemiological data indicate that type 2 diabetes (T2DM) is a significant comorbid risk factor for developing late onset AD [4, 5, 7], suggesting a causal link between insulin dysfunction and AD pathogenesis [5,[8][9][10][11]. Growing body of evidence suggests that insulin dyshomeostasis is fundamental to the development of sAD [4,[12][13][14][15][16][17][18][19], designating sAD as type 3 diabetes [20][21][22]. Type 2 diabetes and Alzheimer's disease share several commonalities including impaired glucose metabolism, increased oxidative stress, inflammation, insulin resistance and amyloidosis, contributing to the overlapping pathology thereby compounding disease symptoms and progression [23]. The risk of developing AD in diabetic patients remains strong even when vascular factors are regulated, suggesting a non-vascular role of insulin in inducing AD pathogenesis [24]. Several non-vascular factors seem to contribute to the increased risk of AD in type 2 diabetes, including defects in insulin signaling, increased production and reduced degradation of Aß, and hyperphosphorylation of tau protein [24, 25].
Introduction
memory. Since the animals were tested for "spontaneous" behavior, each animal was subjected to Y-maze test only once. Spontaneous working memory for each animal was recorded, individual values used to derive a group mean, and analyzed.
Immunohistochemistry
Immunohistochemical analysis of synaptophysin, Aß, and phospho-tau distribution in hippocampus was performed using Sternberger's peroxidase-anti-peroxidase (PAP) technique as established [49, 51, [53] [54] [55] . Briefly, Sections were deparaffinized, hydrated, endogenous peroxidase quenched in methanolic 0.6% H 2 O 2 for 30 min at room temperature (RT), and washed in the wash solution [10 mM Tris-HCl (pH 7.6), 0.5% bovine serum albumin and 0.87% NaCl], 3 times for 5 min each. After this step, all incubations will be performed in a humid chamber at RT. Sections were incubated with; (a) 5% non-immune host serum (in which the primary antibody is produced) for 60 min; [59, 60, [64] [65] [66] [67] . Specifically, GSK3ß is expected to phosphorylate number of PHF-tau epitopes including serine (46, 198, 199, 202, 235, 262, 356, 396, 400, 413) and threonine (181, 205, 212, 217, 231, 403, 404) sites.
The immunoreactivities (IR) for active and inactive forms of GSK3ß were quantitated by western blot analysis of the brains from diabetic and non-diabetic SAMP8 and SAMPR1 mice as established [54] [55] [56] [57] [58] . Briefly, brains were homogenized in modified RIPA buffer containing protease/phosphatase inhibitors cocktail (Sigma), sonicated for 30s, and centrifuged at 100,000g for 1h at 4 o C. Supernatants were subjected to protein estimation (Pierce). Samples containing 50µg of protein were electrophoresed on NuPage 4-12% Bis-Tris precast gels (Life Technologies) under reducing conditions using NuPage MES SDS Running Buffer (Life Technologies). Separated proteins were transferred on PVDF membranes. Membranes were washed and blocked with 5% dry milk in TBST, reacted with optimally diluted primary antisera raised against anti-Y216 GSK3ß (BioSource, recognizing GSK3ß phosphorylated at tyrosine 216 site-activated form of GSK3ß), and raised against anti-S9 GSK3ß (BioSource, recognizing GSK3ß phosphorylated at serine 9 site-inactive form of GSK3ß), washed and reacted with secondary HRP conjugated antibody, washed, developed with Electrochemiluminescence (ECL) (Pierce), and quantitated using Kodak X-5100R. Values were normalized with total GSK3ß-IR.
Statistical analysis
Statistical analysis of the data was performed using GraphPad Prism Program. Data were analyzed to obtain group means with standard deviation (SD). The data were further subjected to omnibus analysis of variance (ANOVA) to determine if there is a main effect of the treatment across the groups, followed by Tukey posthoc test for comparisons between control and experimental groups. Morris water maze spatial learning data was analyzed by repeated measures analysis of variance (RMANOVA) followed by Tukey post hoc test. A value of p<0.05 was considered statistically significant.
Results

Development of Experimental Type 2 Diabetes in SAMP8 and SAMPR1 Mice
Feeding of high fat diet (HF) exhibited exponential increase in body weight both in SAMP8 and SAMPR1 mice up to 12 weeks of HF feeding, in contrast to low fat control diet (LF) fed mice at the parallel time-points. Consistent with previous reports [44] , experimental induction of Type 2 diabetes both in SAMP8 and SAMPR1 mice was evident at 8 weeks of HF feeding, as observed by time-dependent increase in fasting blood glucose levels, peaking at 8 weeks of HF feeding, parallel with gain in body weight, sustained up to 12 weeks. It was observed that the fasting blood glucose levels exponentially increased by 2.6-2.9-fold from week 1 up to12 weeks of HF feeding. Both in SAMP8 and SAMPR1 mice, insulin levels were increased by 8 weeks of HF feeding, sustained up to 12 weeks (Table 1) .
Persistent high blood glucose levels between 20-90 min of GTT test at 8 and 12 weeks post HF treatment both in SAMP8 and SAMPR1 mice indicate systemic failure to reduce blood glucose indicating sustained pancreatic dysfunction due to insulin resistance by 8 weeks post-HF continued up to 12 weeks post-HF diet (Fig. 2) . These results confirm that both SAMP8 and SAMPR1 mice developed insulin resistant T2DM by 8 weeks of HF treatment and that this condition was sustained up to 12 weeks post HF treatment.
Learning and Memory Deficits were further Aggravated in Diabetic SAMP8 Mice
Aging-resistant non-diabetic SAMPR1 mice fed with LF control diet exhibited base-line spatial acquisition learning behavior with the latencies to reach the submerged platform ranging between 15-11s from day1 through day3 learning trials (Fig. 2, open squares) . This performance was deteriorated by 1.4-fold (p<0.05) in diabetic SAMPR1 mice fed with HF diet (Fig. 2 , compare filled squares to open squares). When compared to LF-fed non-diabetic SAMPR1 mice, LF-fed non-diabetic SAMP8 mice exhibited 1.6-fold (p<0.05) deterioration in spatial learning (Fig. 2 , compare open squares to open circles). Diabetic SAMP8 mice fed with HF diet exhibited maximum deficits in spatial learning as evidenced by 1.4-fold (p<0.05) deterioration compared to LF-fed non-diabetic SAMP8 mice (Fig. 2 , compare filled circles to open circles); 1.6-fold deterioration (p<0.05) compared to HF-fed diabetic SAMPR1 mice (Fig.   2 , compare filled circles to filled squares); and maximum deterioration of 2.4-fold (p<0.0001) compared to LF-fed non-diabetic SAMPR1 mice (Fig. 2, compare filled circles to open squares).
Thus, diabetic SAMP8 mice showed maximally impaired spatial acquisition learning.
With regard to retention memory, however, the trend was slightly different in diabetic SAMPR1 mice versus non-diabetic SAMP8 mice. Aging-resistant non-diabetic SAMPR1 mice fed with LF control diet exhibited excellent retention memory profile with the most time (~53s) spent in the quadrant that previously contained the submerged platform (PQ) (Fig. 3, PQ) , and the least time (~7s) spent in other quadrants (Fig. 3, Q1 The reference working memory profile evaluated by spontaneous exploration using Y maze, in SAMP8 and SAMPR1 mice with and without diabetes was observed to be similar to the acquisition learning index. Aging-resistant non-diabetic SAMPR1 mice fed with LF diet exhibited preserved reference working memory showing maximum amount of exploration and alterations in all arms (~140s) (Fig. 4 , SAMPR1-LF), which was moderately impaired by 1.3-fold (p<0.05) in diabetic SAMPR1 mice fed with HF diet showing relatively reduced amount of explorations and alterations (~107s) (Fig. 4, SAMPR1-HF) . Compared to LF-fed non-diabetic SAMPR1 mice, LF-fed non-diabetic SAMP8 mice exhibited 1.8-fold (p<0.05) impairment in reference working memory (Fig. 4) . Diabetic SAMP8 mice exhibited maximum working memory deficits as observed by 2.6-fold deterioration (p<0.003) compared to non-diabetic SAMPR1 mice (Fig. 4) . Thus, diabetic SAMP8 mice showed maximally impaired working reference memory. These results indicate that compared to "aging" alone, "diabetes" by itself was more effective in deteriorating retention memory; while compared to "diabetes" alone, "aging" by itself was more effective in deteriorating acquisition learning and spontaneous exploration; and that diabetic SAMP8 mice exhibited maximum deterioration in all behavioral tasks.
Superfluous elevation of cerebral amyloid in diabetic SAMP8 mice
ELISA profile of cerebral Aß showed that the levels of sAß 40 and sAß 42 in SAMPR1 mice fed either with HF or with LF were not observed to be significantly different (Fig. 5) . Levels of sAß 40 and sAß 42 in LF-fed SAMP8 mice were observed to 3.5-fold (p<0.003) greater than those of HF-or LF-fed SAMPR1 mice indicating that the base levels of sAß 40 and sAß 42 in SAMP8 mice were greater than SAMPR1 mice (Fig. 5) . HF treatment in SAMP8 mice significantly elevated levels of sAß 40 and sAß 42 , both compared to LF-fed SAMP8 mice ( 3.5-fold, p<0.003) and compared to HF-or LF-fed SAMPR1 mice ( 6.5-fold , p<0.0001) (Fig. 5) , indicating that diabetic SAMP8 mice showed most significantly increased levels of cerebral sAß 40 and sAß 42 .
Immunohistochemical profile of cerebral Aß showed faint intraneuronal deposition of 4G8-IR Aß in the brains of non-diabetic SAMP8 mice within the hippocampal neurons (Fig. 6A , inlet, arrowheads) but there was no parenchymal Aß deposition (Fig. 6A) . On the other hand, diabetic SAMP8 mice exhibited increased deposition of intraneuronal Aß (Fig. 6B , inlet, arrowheads) as well as parenchymal deposition of Aß (Fig. 6 ) in the hippocampus, indicating that HF-diet induced diabetic SAMP8 mice showed increased cerebral Aß deposition both within the neurons and parenchyma, leaning towards Alzheimer-like changes. Densitometric quantitation confirmed the increase of 4G8-IR Aß both in the CA1-3 and DG hippocampal subfields. LF-fed nondiabetic SAMPR1 mice showed base levels of 4G8-IR in the CA1-3 and DG hippocampal subfields which were increased by 1.8-fold (p<0.05) in CA1-3, and increased by 2.0-fold (p<0.05) in DG of both HF-fed diabetic SAMPR1 mice and LF-fed non-diabetic SAMP8 mice (Fig. 7) . Compared to both HF-fed diabetic SAMPR1 mice and LF-fed non-diabetic SAMP8 mice, HF-fed diabetic SAMP8 mice exhibited maximum deposition of 4G8-IR Aß (CA1-3, 1.7-fold, p<0.05; DG, 2.2-fold, p<0.004) (Fig. 7) .
Evidence of tau phosphorylation in diabetic SAMP8 mice
Parallel to the exaggeration of cerebral amyloid, an increased trend of tau phosphorylation in diabetic SAMP8 mice was observed, as evidenced by increased immunoreaction (IR) of phospho-tau (AT8). Immunohistochemical index of Phospho-tau (AT8) showed that there was a subtle deposition of AT8-IR in the hippocampal neuronal processes in the brains of non-diabetic SAMP8 mice (Fig. 6C , inlet, arrowhead), which was found to increase in the hippocampal neuronal processes of diabetic SAMP8 mice (Fig. 6D , inlet, arrowheads) suggesting that HFdiet induced type 2 diabetes in SAMP8 mice promoted increased deposition of Phospho-tau, a trend towards Alzheimer-like changes. Densitometric quantitation confirmed increased AT8-IR both in the CA1-3 and DG hippocampal subfields. LF-fed non-diabetic SAMPR1 mice showed base levels of AT8-IR in the CA1-3 and DG hippocampal subfields which were increased by 2.5-fold (p<0.005) in CA1-3, and increased by 2.6-fold (p<0.005) in DG of both HF-fed diabetic SAMPR1 mice and LF-fed non-diabetic SAMP8 mice (Fig. 7) . Compared to both HF-fed diabetic SAMPR1 mice and LF-fed non-diabetic SAMP8 mice, HF-fed diabetic SAMP8 mice exhibited maximally increased AT8-IR (CA1-3, 1.4-fold, p<0.05; DG, 1.5-fold, p<0.002) (Fig. 7) .
With regard to the profile of tau-phosphorylating enzyme GSK3ß, it was observed that active form of GSK3ß (Y216) was prominent in SAMP8 mice while inactive form of GSK3ß (S9) was prominent in SAMPR1 mice regardless of high fat (HF) or low fat (LF) dietary treatments (Fig. 8) . HF or LF dietary treatment did not alter the density of inactive GSK3ß (S9) both in SAMP8 or SAMPR1 mice. Compared to LF-fed non-diabetic SAMP8 mice, HF treatment increased activated GSK3ß (Y216) by 1.6-fold in SAMP8 mice (P<0.004), but not in SAMPR1 mice (Fig. 8 ). Compared to HF/LF-fed SAMPR1 mice, activated GSK3ß (Y216) is increased by 2.2-fold (p<0.0001) in LF-fed, and by 3.5-fold (p<0.0001) in HF-fed SAMP8 mice (Fig. 8) .
Results indicate that cerebral GSK3ß was dysregulated only in diabetic SAMP8 mice, but not in diabetic SAMPR1 or non-diabetic SAMPR1 or SAMP8 mice.
Evidence of aggravated synaptic deficits in diabetic SAMP8 mice
Parallel to the exaggeration of cerebral amyloid and tau pathology, there was observed a marked synaptic deficit in diabetic SAMP8 mice as evidenced by selectively decreased mice were very much similar to those observed for diabetic SAMPR1 mice (compare black arrow, black arrowhead and white arrowhead in Fig. 9C to 9B ). Experimental induction of type 2 diabetes after HF diet to SAMP8 mice, remarkably reduced SYN-IR within the respective hippocampal dendritic fields of diabetic SAMP8 mice (compare black arrow, black arrowhead and white arrowhead in Fig. 9D to 9C ), indicating that SYN-IR was drastically reduced in diabetic SAMP8 mice. hippocampal subfields. LF-fed non-diabetic SAMPR1 mice showed base levels of SYN-IR in the CA3 and DG hippocampal subfields which were decreased by 1.4-fold (p<0.05) in CA3, and decreased by 1.3-fold (p<0.05) in DG of both HF-fed diabetic SAMPR1 mice and LF-fed nondiabetic SAMP8 mice (Fig. 10) . Compared to both HF-fed diabetic SAMPR1 mice and LF-fed non-diabetic SAMP8 mice, HF-fed diabetic SAMP8 mice exhibited maximally decreased SYN-IR (CA3, 1.8-fold, p<0.004; DG, 2.0-fold, p<0.005) (Fig. 10 ). These observations show that although HF diet induced T2DM affected both CA3 and DG with regard to the depletion of SYN-IR, CA3 was relatively more affected than DG. In summary, diabetic SAMP8 mice exhibited Alzheimer-like neuropathological and cognitive signs.
Discussion
Current investigation emphasizes the role of diabetes as a non-familial co-morbid factor in producing Alzheimer-like characteristics when combined with accelerated aging. Current study clearly showed aggravating effects of insulin dysfunction even after a shortly sustained experimental T2DM on the development of early Alzheimer-like neuropathological and cognitive impairments, indicating that further sustainment of T2DM in SAMP8 mice has a potential to develop characteristic features typifying the disease. Current data implicate that although "aging" by itself promotes Aß production, "aging" alone is not sufficient to aggravate pathological accumulation of Aß, unless accompanied with other co-morbid factor(s)-such as insulin dysfunction. Aging alone is known to elevate oxidative damage and inflammation [85, 86] . On the other hand, diabetes by itself is known to produce inflammation and oxidative damage [87] [88] [89] [90] . Therefore, when "aging" and "diabetes" are combined, chronic oxidative damage [91, 92] and neuroinflammation [93, 94] , independently resulting from aging and diabetes, lead to "exacerbation" of Aß production. Moreover, diabetes is known to reduce Aß clearance [17, 95] and speed up Aß fibrillogenesis via GM1 ganglioside
[83], adding to the accumulation of Aß. Aß in turn is known to make the neurons resistant to insulin [95, 96] , thus setting up a vicious interplay of Aß and insulin resistance. Based on these facts, Aß cascade does exist; however, compounded consequences of aging and diabetes make it worst. Oxidative damage and neuroinflammation in aging brain and diabetes appear to reside upstream of exaggerated production and accumulation of Aß. Consist with experimental and clinical reports [87, [96] [97] [98] [99] [100] , current data show that diabetes "adds" to the oxidative and inflammatory effects produced by aging, and sets up a vicious interplay of Aß and insulin resistance and impaired insulin signaling.
In addition to the amyloidogenic effects of insulin dysfunction, experimental evidence also suggests its role in promoting synaptic and cognitive deficits. Mice with systemic insulin deficiency display an evidence of reduced insulin signaling in the brain that is associated with synaptic and behavioral features of AD [15] . Type 2 diabetes associated with insulin resistance show reduced insulin brain uptake and content, suggesting that brain insulin receptors become less sensitive to insulin, which could reduce synaptic plasticity [74] . Impaired insulin signaling is shown to decrease the trafficking and function of postsynaptic glutamate receptors leading synaptic deficits and memory loss [34] . Since insulin acts as a "neuromodulator", it may influence release and re-uptake of neurotransmitters improving memory [97] , and promote dendritic spine formation and excitatory synapse development [101] . Thus, insulin dysfunction may lead to synaptic and cognitive deficits [102] . Supporting evidence in this regard indicates that brain depletion of insulin receptor substrate 2 disrupts hippocampal synaptic plasticity [103] .
In high fat fed diabetic mice, significant impairment in hippocampal long term potentiation (LTP) is observed [104] , and decreased spontaneous alteration in Y maze accompanied by decreased density of Syanptophysin and SNAP25 nerve terminal markers are observed [105] .
Consistent with these reports, our data show that while low fat diet maintained strong synaptophysin immunoreactivity within the hippocampal CA3 dendritic field as well as within the supra-granular and sub-granular molecular layers of dentate gyrus of SAMPR1 mice, development of diabetes resulted in the reduction of synaptophysin immunoreactivity only in the CA3 dendritic field that receives inputs from entorhinal cortical perforant pathway, while preserving synaptophysin immunoreactivity within the supra-granular and sub-granular molecular layers of dentate gyrus, that project to the CA3 via mossy fiber connections. Since CA3 hippocampal sub-region is essential for the consolidation and retrieval of spatial memory, observed depletion of synaptophysin immunoreactivity in the CA3 subfield would indicate that independent of "aging", diabetes alone may affect memory retrieval. In that regard, it is interesting to note that high-fat fed diabetic SAMPR1 mice exhibited worsened retention memory than the non-diabetic SAMP8 mice.
By contrast, preserved synaptophysin immunoreactivity in the CA3 dendritic field, but depletion of synaptophysin immunoreactivity within the supra-granular and sub-granular molecular layers of dentate gyrus in non-diabetic SAMP8 mice, indicate that "aging alone" in absence of diabetes may not disrupt consolidation and retrieval of spatial memory, but may impair the formation of new memories (learning or exploration). Consistent with this theory, current results confirm greater deterioration of learning and spontaneous exploration nondiabetic SAMP8 mice than those of diabetic SAMPR1 mice. Combining accelerated aging with diabetes exhibited depletion of synaptophysin immunoreactivity both in the CA3 dendritic fields and within the supra-granular and sub-granular molecular layers of dentate gyrus, which was reflected in the drastic deterioration of learning, memory and spontaneous exploration.
With regard to tau biology, insulin deficiency has been shown to promote pathological phosphorylation of tau in various models of insulin dysfunction. Tau has been found to be phosphorylated at multiple sites in mouse brain after streptozotocin (STZ)-induced insulin deficiency [25, 106] . Alteration in glycogen kinase synthase 3 beta (GSK3ß) and deficits in hippocampal synaptic transmission with parallel deficits in hippocampal long term potentiation (LTP) has been observed in STZ-injected rodents [34] . Consistent with these earlier reports, abundant expression of activated form of GSK3ß in diabetic SAMP8 mice actively involved in tau phosphorylation indicate that the index of tau phophorylation is quite pronounced when aging and diabetic condition is combined. As a matter of fact, these mice also showed structured "tangle-like" inclusions within the hippocampal neuronal processes as compared to the non-diabetic SAMP8 mice. Thus, the tau-phosphorylation profile seems to run in parallel with other degenerative changes and cognitive decline observed in diabetic SAMP8 mice. [46] Sullivan KA, Lentz SI, Roberts JL, Jr., Feldman EL (2008) Criteria for creating and assessing mouse models of diabetic neuropathy. Curr Drug Targets 9, 3-13. Table 1 Effect of high-fat (HF) or low-fat (LF) diet on the levels of serum insulin (µg/l), blood HbA1c (%), brain insulin (pg/mg), Cytochrome c Oxidase (COX) and Pyruvate Dehydrogenase (PDH) (pg/mg) in SAMP8 and SAMPR1 mice. Note that compared to low-fat fed non-diabetic SAMPR1 mice, spatial acquisition learning was observed to be gradually worsened from high-fat fed diabetic SAMPR1 mice (1.4-fold) > low-fat fed non-diabetic SAMP8 mice (1.6-fold) > high-fat fed diabetic SAMP8 mice (2.4-fold). Data indicate the most significantly deteriorated spatial acquisition learning in diabetic SAMP8 mice. hippocampal neurites in non-diabetic SAMP8 mice (Fig. 6C , inlet, arrowhead) merely due to accelerated aging, which was remarkably increased in the CA hippocampal CA1 of diabetic SAMP8 mice (Fig. 6D , inlet, arrowheads) as a result of accelerated aging compounded with diabetes. Scale bars in A, B, C, D = 100 μm; Scale bars in all inlets = 20 μm. derived from average individual values for each group. Note that both high fat fed diabetic SAMPR1 mice and low fat fed non-diabetic SAMP8 mice showed more or less similar pattern of 4G8-IR Aß and AT8-IR phospho-tau within Ca1-3 and DG, which were 1.8-2.0-fold higher for 4G8-IR and 2.5-2.6-fold higher for AT8-IR than the low fat fed non-diabetic SAMPR1 mice. phosphorylated at tyrosine 216 site-activated form of GSK3ß (anti-Y216 GSK3ß) and at serine 9 site-inactive form of GSK3ß (anti-S9 GSK3ß) (BioSource International). In general, density for activated GSK3ß (Y216) is greater in the brains of SAMP8 mice than that of SAMPR1 mice. By contrast, density for inactive form of GSK3ß (S9) is greater in the brains of SAMPR1 mice than that of SAMP8 mice. HF treatment did not affect the reaction for inactive GSK3beta (S9) in the brains of SAMP8 mice. HF treatment increased the density for activated GSK3ß (Y216) only in the brains of SAMP8 mice, but not in the brains of SAMPR1 mice, indicating that experimental induction of type 2diabetes in SAMP8 mice promotes abnormal phosphorylation of tau.
Conclusions
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Densitometric analysis showed that compared to LF-fed non-diabetic SAMP8 mice, the levels of GSK3ß (Y216) increased by 1.6-fold (p<0.004) in HF-fed diabetic SAMP8 mice. Compared to LF-or HF-fed non-diabetic or diabetic SAMPR1 mice, the levels of GSK3ß (Y216) increased by 2.2-fold (p<0.0001) in HF-fed diabetic SAMP8 mice. (Fig. 9A, arrow) , and within the supra-granular (Fig. 9A, black arrowhead) and infragranular (Fig. 9A , white arrowhead) molecular layers of dentate gyrus of non-diabetic SAMPR1 mice. Note that experimental induction of diabetes in SAMPR1 mice resulted in the reduction of SYN immunoreactivity only in the CA3 dendritic field (Fig. 9B, black arrowhead), while preserving SYN immunoreactivity within the supra-granular (Fig. 9B, black arrowhead) and infragranular (Fig. 9B , white arrowhead) molecular layers of dentate gyrus of diabetic SAMPR1 mice. On the other hand, in non-diabetic SAMP8 mice, SYN immunoreactivity in the CA3 dendritic field (Fig. 9C, black arrowhead) was preserved, but the SYN immunoreactivity within the supra-granular (Fig. 9C, black arrowhead) and infragranular (Fig.   9C , white arrowhead) molecular layers of dentate gyrus was reduced. In the hippocampus of diabetic SAMP8 mice, SYN immunoreactivity in all CA3 (Fig. 9D, arrow) and respective dentate gyrus subfields (Fig. 9D , black arrowhead and while arrowhead) were observed to be greatly reduced. Scale bar = 100 μm. 
